Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Immunogenicity of Sinovac EV71 Vaccine in Children 36-71 Months
NCT03909074Phase 3Completed
- Sponsor
- Sinovac Biotech Ltd.
- Start
- Mar 2019
- Primary completion
- Jun 2019
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
A Phase 3 trial of enterovirus 71 vaccine (vero cell), inactivated in HIV-associated central nervous system involvement (HAND), sponsored by Sinovac Biotech Ltd.. Started Mar 2019; status: completed.
02
Drugs
enterovirus 71 vaccine (vero cell), inactivated
03
Conditions
HIV-associated central nervous system involvement (HAND)
Beyond the preview
Go deeper on NCT03909074.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03909074.